Suggested remit: To appraise the clinical and cost effectiveness of ustekinumab within its marketing authorisation for treating moderately to severely active ulcerative colitis.
 
Status In progress
Process STA 2018
ID number 1511

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Janssen
Others Department of Health and Social Care
  NHS England
Patient carer groups Crohn's and Colitis UK
Professional groups British Society of Gastroentrology
  Royal College of Physicians
  United Kingdom of Clinical Pharmacy

Commentators

Comparator companies Amgen
  Pfizer
  Takeda
  Sandoz
General commentators British National Formulary
  Department of Health and Social Services and Public Safety,
  Healthcare Improvement ScotlandNorthern Ireland (DHSSPSNI)
  Welsh Health Specialised Services Committee
  Scottish Medicines Consortium

Timeline

Key events during the development of the guidance:

Date Update
28 April 2020 - 13 May 2020 Final appraisal document
20 April 2020 Topic update: The decision to pause this appraisal has been re-considered. This topic has now been defined as therapeutically critical and development will continue.
02 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
25 February 2020 Committee meeting: 2
21 January 2020 - 11 February 2020 Appraisal consultation
10 December 2019 Committee meeting: 1
10 April 2019 In progress, In progress
10 April 2019 Invitation to participate
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance